People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology, Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Syros Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $296.1M | $2.6B | 2018 |
| Alumis Inc. | — | Biotechnology | Series D+ | $240.0M | $433.1M | 2024 |
| Chinook Therapeutics U.S., Inc. | — | Biotechnology | Series D+ | $180.0M | $4.5B | 2020 |
| Aravive, Inc. | — | Biotechnology | Series C | $156.1M | $702.9M | 2011 |
| OrsoBio, Inc. | — | Biotechnology | Series C | $124.6M | $340.8M | 2023 |
| Mineralys Therapeutics, Inc. | — | Pharmaceuticals | Series D+ | $118.0M | $2.4B | 2022 |
| Principia Biopharma Inc. | — | Biotechnology | Series C | $77.4M | $2.0B | 2015 |
| Presidio Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $72.6M | $742.2M | 2009 |
| Tentarix Biotherapeutics, LP | — | Biotechnology | Series B | $43.0M | $358.6M | 2020 |
| Seattle Genetics Inc /Wa | — | Other | Series A | $11.5M | $173.3M | 2009 |
Srinivas Akkaraju at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Srinivas Akkaraju on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jerel Davis | 2 | 13 |
| Alan Colowick | 2 | 7 |
| MICHAEL DYBBS | 2 | 5 |
| Felix Baker | 2 | 4 |
| Cory Freedland | 2 | 3 |
| MARTIN BABLER | 2 | 2 |
| Robert Nelsen | 1 | 22 |
| Peter Thompson | 1 | 16 |
| Amir Nashat | 1 | 14 |
| Kevin Johnson | 1 | 12 |
| Anthony Sun | 1 | 8 |
| Simeon George | 1 | 8 |
| Matthew Young | 1 | 7 |
| Derek DiRocco | 1 | 7 |
| Richard Gaster | 1 | 7 |
| Vicki Sato | 1 | 6 |
| James Tananbaum | 1 | 6 |
| Kenneth Galbraith | 1 | 6 |
| PAUL Grayson | 1 | 5 |
| Noubar B Afeyan | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.